Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Access to quality cancer care is still a big issue in Europe, and there is great heterogeneity in the availability of drugs, screening programmes and resources among countries. Neglected cancer populations exist with lower rates of early diagnosis and treatment compliance
The international community of high-standard palliative programmes is growing as the prestigious title is accredited to 18 new cancer centres
ESMO Open is dedicated to publishing high-quality medical research and educational content from all disciplines of oncology, with a focus on innovative clinical and translational cancer research. The first articles will be published in January 2016.
New award will will acknowledge someone who has actively worked to sensitise organisations to perceive the female oncology workforce as a valuable resource
We are pleased to announce the winners of the ESMO Award, ESMO Lifetime Achievement Award and Hamilton Fairley Award
The course aims to attract medical students to the medical oncology profession to ensure there are sufficient numbers to care for the rising numbers of cancer patients
Patients with metastatic colorectal cancer (mCRC) that are mutation-free in the KRAS, NRAS, BRAF and PIK3CA genes showed significant benefit from continuing anti-epidermal growth factor receptor (EGFR) therapy beyond progression following first-line chemotherapy and an anti-EGFR monoclonal antibody
Researchers announced that the phase IIIb CONSIGN study has confirmed the benefit, with safety profile and progression free survival similar to phase III trial results
The multicentre, open label, randomised phase III trial evaluated the NK1 antagonist aprepitant for the prevention of nausea and vomiting induced by oxaliplatin-based chemotherapy in Japanese patients with colorectal cancer
A total of 6,128 patients were included in the analysis, which showed that patients with the lowest BMI had a significantly shorter overall survival than patients in the other BMI categories
The ESMO President for the 2018-2019 period will be Josep Tabernero
The scale offers a rational, structured and consistent approach to ‘stratify’ a drug’s clinically meaningful benefit
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
